EV-302/KEYNOTE-A39 trial: Subgroup analyses

Dr Michiel Van Der Heijden, a medical oncologist at the Netherlands Cancer Institute, Amsterdam, Netherlands, presented subgroup analyses from the EV-302/KEYNOTE-A39 trial. 

The analyses demonstrated that the efficacy outcomes for both the cisplatin-eligible and cisplatin-ineligible cohorts were consistent with those observed in the overall study population. Additionally, the safety profile of the treatment regimen was generally manageable, with no new safety signals identified. These findings support the adoption of enfortumab vedotin in combination with pembrolizumab as a new standard-of-care for patients with previously untreated locally advanced or metastatic urothelial carcinoma.